GHRP-6 Side Effects and Safety
Reported GHRP-6 side effects, contraindications, and safety signals.
Safety
Safety & Contraindications
GHRP-6 is a research compound and is not FDA-approved for general use. It should be avoided by anyone with active malignancy and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
Safety
What to Monitor
Track prolactin, IGF-1, and fasting glucose while you're running GHRP-6 so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- active malignancy
- pregnancy
References
- GHRP-6 and the discovery of the ghrelin receptor
- Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
- Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome.
- Synthetic Growth Hormone-Releasing Peptides (GHRPs) - NIH